Valtoco (Diazepam) Patent Expiration, LOE Window & CMS Spending
Valtoco (Diazepam) by Neurelis: FDA Orange Book LOE 2042-06-10, 11 AB generics, $162.4M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Neurelis |
| FDA Application & Pathway | N211635 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2042-06-10 |
| Orange Book Patents (*PED Extensions) | 8 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 11 |
| 2024 CMS Total Public Spend | $162.4M |
| 2024 Medicare Part D Spend | $24.4M |
| 2024 Medicaid Spend | $138.0M |
| Reported Wholesale Price Change (CA SB 17) | 6 WAC filings (max 18.5% 2-yr change) |